MicroRNA-454 inhibits non‑small cell lung cancer cells growth and metastasis via targeting signal transducer and activator of transcription-3 Retraction in /10.3892/mmr.2022.12768

Liu,Shuliang; Ge,Xingping; Su,Lingfei; Zhang,Aifeng; Mou,Xuri

doi:10.3892/mmr.2017.8350

MicroRNA-454 inhibits non‑small cell lung cancer cells growth and metastasis via targeting signal transducer and activator of transcription-3

Retraction in: /10.3892/mmr.2022.12768

Authors:
- Shuliang Liu
- Xingping Ge
- Lingfei Su
- Aifeng Zhang
- Xuri Mou
View Affiliations

Affiliations: Department of Thoracic Surgery, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China, Department of Radiotherapy, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China, Department of Outpatient, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China
Published online on: December 27, 2017 https://doi.org/10.3892/mmr.2017.8350
Pages: 3979-3986

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most common type of cancers and the leading cause of cancer‑related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for >80% of lung cancer cases. Emerging studies have suggested that microRNAs are dysregulated in NSCLC and serve important roles in NSCLC initiation and development. However, to the best of our knowledge, the expression, roles and molecular mechanism of microRNA‑454 (miR‑454) have not been investigated in NSCLC. In the present study, miR‑454 was demonstrated to be significantly downregulated in NSCLC tissues and cell lines, as assessed by western blot analysis and reverse transcription‑quantitative polymerase chain reaction. Reduced miR‑454 expression was significantly correlated with aggressive clinicopathological features in NSCLC. In addition, upregulation of miR‑454 suppressed proliferation, migration and invasion NSCLC cells, as assessed by Cell Counting Kit‑8 and in vitro migration and invasion assays, respectively. Furthermore, bioinformatics analysis identified STAT3 as a direct target gene of miR‑454, and STAT3 knockdown was demonstrated to simulate the effects of miR‑454 overexpression in NSCLC. In conclusion, the present study provided convincing evidence that miR‑454 is downregulated in NSCLC, and regulates growth and metastasis by directly targeting STAT3, which suggests that miR‑454 may be an efficient therapeutic target for NSCLC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wang F, Zhou J, Zhang Y, Wang Y, Cheng L, Bai Y and Ma H: The value of microRNA-155 as a prognostic factor for survival in non-small cell lung cancer: A meta-analysis. PLoS One. 10:e01368892015. View Article : Google Scholar : PubMed/NCBI
3	Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L and Kunkler I; EUROCARE-4 Working Group, : Recent cancer survival in Europe: A 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
4	Gupta GP and Massagué J: Cancer metastasis: Building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI
5	Chen C, Zhao Z, Liu Y and Mu D: MicroRNA-99a is downregulated and promotes proliferation, migration and invasion in non-small cell lung cancer A549 and H1299 cells. Oncol Lett. 9:1128–1134. 2015. View Article : Google Scholar : PubMed/NCBI
6	Li Y, Li Y, Liu J, Fan Y, Li X, Dong M, Liu H and Chen J: Expression levels of microRNA-145 and microRNA-10b are associated with metastasis in non-small cell lung cancer. Cancer Biol Ther. 17:272–279. 2016. View Article : Google Scholar : PubMed/NCBI
7	Zhang Y, Yang X, Wu H, Zhou W and Liu Z: MicroRNA-145 inhibits migration and invasion via inhibition of fascin 1 protein expression in non-small-cell lung cancer cells. Mol Med Rep. 12:6193–6198. 2015. View Article : Google Scholar : PubMed/NCBI
8	Li D, Wei Y, Wang D, Gao H and Liu K: MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways. Biochem Biophys Res Commun. 472:465–470. 2016. View Article : Google Scholar : PubMed/NCBI
9	Gee GV, Koestler DC, Christensen BC, Sugarbaker DJ, Ugolini D, Ivaldi GP, Resnick MB, Houseman EA, Kelsey KT and Marsit CJ: Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 127:2859–2869. 2010. View Article : Google Scholar : PubMed/NCBI
10	Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006. View Article : Google Scholar : PubMed/NCBI
11	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
12	Donadeu FX, Schauer SN and Sontakke SD: Involvement of miRNAs in ovarian follicular and luteal development. J Endocrinol. 215:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
13	Liwak U, Faye MD and Holcik M: Translation control in apoptosis. Exp Oncol. 34:218–230. 2012.PubMed/NCBI
14	Rutnam ZJ and Yang BB: The involvement of microRNAs in malignant transformation. Histol Histopathol. 27:1263–1270. 2012.PubMed/NCBI
15	Joshi P, Middleton J, Jeon YJ and Garofalo M: MicroRNAs in lung cancer. World J Methodol. 4:59–72. 2014. View Article : Google Scholar : PubMed/NCBI
16	Chen T, Gao F, Feng S, Yang T and Chen M: MicroRNA-370 inhibits the progression of non-small cell lung cancer by downregulating oncogene TRAF4. Oncol Rep. 34:461–468. 2015. View Article : Google Scholar : PubMed/NCBI
17	Wang H, Yan C, Shi X, Zheng J, Deng L, Yang L, Yu F, Yang Y and Shao Y: MicroRNA-575 targets BLID to promote growth and invasion of non-small cell lung cancer cells. FEBS Lett. 589:805–811. 2015. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Li D, Li DQ, Liu D and Tang XJ: miR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer. Cell Oncol (Dordr). 39:139–147. 2016. View Article : Google Scholar : PubMed/NCBI
20	Cortinovis D, Monica V, Pietrantonio F, Ceresoli GL, La Spina CM and Wannesson L: MicroRNAs in non-small cell lung cancer: Current status and future therapeutic promises. Curr Pharm Des. 20:3982–3990. 2014. View Article : Google Scholar : PubMed/NCBI
21	Boeri M, Pastorino U and Sozzi G: Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 18:268–274. 2012. View Article : Google Scholar : PubMed/NCBI
22	Nishijima N, Seike M, Soeno C, Chiba M, Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K and Gemma A: miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. Int J Oncol. 48:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
23	Hou Y, Zhen J, Xu X, Zhen K, Zhu B, Pan R and Zhao C: miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer. Oncol Lett. 10:1985–1992. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhou YL, Xu YJ and Qiao CW: miR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp Pathol. 8:6312–6322. 2015.PubMed/NCBI
25	Sun L, Wang Q, Gao X, Shi D, Mi S and Han Q: MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma. FEBS Lett. 589:2791–2796. 2015. View Article : Google Scholar : PubMed/NCBI
26	Liang HL, Hu AP, Li SL, Xie JP, Ma QZ and Liu JY: miR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression. Asian Pac J Cancer Prev. 16:2397–2402. 2015. View Article : Google Scholar : PubMed/NCBI
27	Zhou L, Qu YM, Zhao XM and Yue ZD: Involvement of miR-454 overexpression in the poor prognosis of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 20:825–829. 2016.PubMed/NCBI
28	Niu G, Li B, Sun J and Sun L: miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met. Cell Prolif. 48:348–355. 2015. View Article : Google Scholar : PubMed/NCBI
29	Fang B, Zhu J, Wang Y, Geng F and Li G: miR-454 inhibited cell proliferation of human glioblastoma cells by suppressing PDK1 expression. Biomed Pharmacother. 75:148–152. 2015. View Article : Google Scholar : PubMed/NCBI
30	Fan Y, Xu LL, Shi CY, Wei W, Wang DS and Cai DF: MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma. Sci Rep. 6:227932016. View Article : Google Scholar : PubMed/NCBI
31	Yu L, Gong X, Sun L, Yao H, Lu B and Zhu L: miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma. Oncotarget. 6:39225–39234. 2015. View Article : Google Scholar : PubMed/NCBI
32	Wagner KU and Schmidt JW: The two faces of Janus kinases and their respective STATs in mammary gland development and cancer. J Carcinog. 10:322011. View Article : Google Scholar : PubMed/NCBI
33	Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, et al: Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
34	Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL and Rimm DL: Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res. 9:594–600. 2003.PubMed/NCBI
35	Nagpal JK, Mishra R and Das BR: Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer. 94:2393–2400. 2002. View Article : Google Scholar : PubMed/NCBI
36	Song L, Turkson J, Karras JG, Jove R and Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
37	Yin Z, Zhang Y, Li Y, Lv T, Liu J and Wang X: Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells. Acta Histochem. 114:151–158. 2012. View Article : Google Scholar : PubMed/NCBI
38	Zhu BR, Cai JM, Tang GS, Li BL, Gao F, Cui JG and Liu HC: Effects of STAT3 antisense oligonucleotide on proliferation and apoptosis of non-small cell lung cancer cell line A549. Ai Zheng. 26:820–827. 2007.(In Chinese). PubMed/NCBI
39	Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI